OMCL

Omnicell is a stable but stagnant healthcare-automation franchise, not a grower. Revenue of $1.18B (+6.5%) sits squarely inside the $1.11B–$1.30B band the company has bounced around for five years (FY21 $1.13B → FY22 $1.30B → FY23 $1.15B → FY24 $1.11B → FY25 $1.18B), so the top line shows no durable trend. The bigger problem is profitability: net income has collapsed from $77.8M in FY21 to just $2.05M in FY25 (-83.6% YoY), leaving operating margin at 0.4%, net margin at 0.2% and ROE at 0.2%. On GAAP earnings the stock is uninvestable on a P/E basis (1023x is a meaningless artifact of near-zero EPS).

The redeeming feature is cash. Despite negligible accounting profit, operating cash flow was $127M and, after $40.4M capex, free cash flow is roughly $87M — the gap is largely $78.8M of D&A weighing on GAAP results. That puts the stock near ~21x P/FCF (EV/FCF ~20x) at a $1.86B cap and 1.6x sales, which is fair rather than cheap. The balance sheet supports patience: equity $1.23B against $743M liabilities (0.60x), a 1.43x current ratio, and only ~$50M long-term debt. Management is returning that cash — $77.6M of buybacks trimmed the share count 2.8% — though cash on hand fell 46.8% to $197M, partly funding those repurchases.